Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Jessica Sharpe

Vanderbilt University Medical Center

Jessica Sharpe is a third-year oncology fellow at Vanderbilt University Medical Center and will be joining the faculty at Vanderbilt as an Assistant Professor in the breast oncology group in July this year. She has an interest in immunotherapy and its uses in breast cancer as well as toxicities related to immunotherapy. She is also interested in novel treatment combinations to improve care and outcomes for breast cancer patients and is involved in several clinical trials at Vanderbilt.